Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Sees Significant Decrease in Short Interest
by Teresa Graham · The Cerbat GemXtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT – Get Free Report) was the recipient of a large drop in short interest during the month of April. As of April 15th, there was short interest totaling 12,780 shares, a drop of 67.8% from the March 31st total of 39,674 shares. Based on an average daily volume of 221,550 shares, the short-interest ratio is currently 0.1 days. Currently, 0.0% of the company’s shares are short sold.
Analyst Ratings Changes
Several analysts recently weighed in on XTNT shares. BTIG Research cut their price objective on Xtant Medical from $1.50 to $1.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. Craig Hallum reiterated a “buy” rating on shares of Xtant Medical in a report on Wednesday, March 18th. Two investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $1.00.
Check Out Our Latest Research Report on Xtant Medical
Xtant Medical Stock Up 2.8%
XTNT stock traded up $0.01 during midday trading on Friday, hitting $0.52. The company’s stock had a trading volume of 149,003 shares, compared to its average volume of 170,295. The company has a quick ratio of 1.63, a current ratio of 2.65 and a debt-to-equity ratio of 0.22. Xtant Medical has a 52-week low of $0.39 and a 52-week high of $0.95. The firm has a market capitalization of $73.41 million, a P/E ratio of 17.48 and a beta of -0.16. The firm has a 50-day simple moving average of $0.56 and a 200-day simple moving average of $0.65.
Xtant Medical (NYSEAMERICAN:XTNT – Get Free Report) last released its quarterly earnings data on Tuesday, March 31st. The medical device company reported $0.03 earnings per share (EPS) for the quarter. The business had revenue of $32.36 million during the quarter, compared to analysts’ expectations of $30.75 million. Xtant Medical had a net margin of 3.71% and a return on equity of 10.27%.
Institutional Investors Weigh In On Xtant Medical
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Nantahala Capital Management LLC raised its stake in Xtant Medical by 500.3% during the 2nd quarter. Nantahala Capital Management LLC now owns 68,394,000 shares of the medical device company’s stock worth $50,543,000 after acquiring an additional 57,000,000 shares in the last quarter. Vanguard Group Inc. raised its stake in Xtant Medical by 4.6% during the 3rd quarter. Vanguard Group Inc. now owns 2,355,671 shares of the medical device company’s stock worth $1,529,000 after acquiring an additional 104,159 shares in the last quarter. Renaissance Technologies LLC raised its stake in Xtant Medical by 28.8% during the 4th quarter. Renaissance Technologies LLC now owns 919,860 shares of the medical device company’s stock worth $721,000 after acquiring an additional 205,945 shares in the last quarter. Hillsdale Investment Management Inc. acquired a new stake in Xtant Medical during the 4th quarter worth $284,000. Finally, Nano Cap New Millennium Growth Fund L P acquired a new stake in Xtant Medical during the 4th quarter worth $220,000. 69.33% of the stock is currently owned by institutional investors and hedge funds.
About Xtant Medical
Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.
The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.